94 related articles for article (PubMed ID: 11327535)
1. Intensive cyclic chemotherapy with unprocessed whole blood support in advanced breast cancer.
Vanásek J; Filip S; Medková V; Bláha M; Maricka P; Stránský P; Vavrová J
Neoplasma; 2001; 48(1):34-8. PubMed ID: 11327535
[TBL] [Abstract][Full Text] [Related]
2. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
3. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
4. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
5. Peripheral progenitor cells (PBPC) in supportive care after high-dose chemotherapy in breast cancer.
Filip S; Bláha M; Petera J; Vavrová J; Knízek J
Neoplasma; 2001; 48(1):39-47. PubMed ID: 11327536
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
7. Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer - follow up at 10 years.
Cinek P; Filip S; Vanasek J; Mericka P; Blaha M; Zouhar M
Exp Oncol; 2007 Jun; 29(2):144-51. PubMed ID: 17704748
[TBL] [Abstract][Full Text] [Related]
8. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
10. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
[TBL] [Abstract][Full Text] [Related]
11. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
12. Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma.
Filip S; Vanásek J; Bláha M; Vávrová J
Neoplasma; 1997; 44(4):212-8. PubMed ID: 9473775
[TBL] [Abstract][Full Text] [Related]
13. Autologous platelet collection and storage to support thrombocytopenia in patients undergoing high-dose chemotherapy and circulating progenitor cell transplantation for high-risk breast cancer.
Torretta L; Perotti C; Pedrazzoli P; Dornini G; Viarengo G; Livraghi A; Noris P; Da Prada GA; Balduini CL; della Cuna GR; Salvaneschi L
Vox Sang; 1998; 75(3):224-9. PubMed ID: 9852411
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
Stemmler HJ; Salat C; Lindhofer H; Menzel H; Untch M; Kahlert S; Konecny G; Sauer H; Ledderose G; Heinemann V; Kolb HJ
Anticancer Res; 2005; 25(4):3047-54. PubMed ID: 16080564
[TBL] [Abstract][Full Text] [Related]
15. [Efficiency of high-dose FEC chemotherapy for the mobilization of hematopoietic stem cells into peripheral blood].
D'Hondt L; André M; Canon JL; Guillaume T; Doyen C; Feyens AM; Chatelain B; Dromelet A; Humblet Y; Longueville J; Symann M
Bull Cancer; 1997 Jul; 84(7):729-33. PubMed ID: 9339199
[TBL] [Abstract][Full Text] [Related]
16. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients.
Carrión R; Serrano D; Gómez-Pineda A; Díez-Martín JL
Bone Marrow Transplant; 2003 Sep; 32(6):563-7. PubMed ID: 12953127
[TBL] [Abstract][Full Text] [Related]
17. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
18. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
19. High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer.
Recchia F; De Fillipis S; Piccinini M; Rea S
Anticancer Res; 2003; 23(5b):4141-7. PubMed ID: 14666615
[TBL] [Abstract][Full Text] [Related]
20. Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer.
Danova M; Perotti C; Mora O; Lucotti C; Torretta L; Comolli G; Riccardi A; Salvaneschi L; Ascari E
Oncol Rep; 1998; 5(2):427-9. PubMed ID: 9468573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
